Recent studies have demonstrated the clinical advantages of using an acetate-free dialysate that contains citrate; acetate promotes inflammation, and replacement of acetate by citrate reduces inflammation.* Citrate chelates calcium ions and inhibits coagulation, providing anticoagulation benefits.
Patients Just Feel Better
“Since dialyzing with CitraPure® Citric Acid I’ve never felt so good! I’ve been on dialysis 6 1/2 years and after every treatment I felt worn out and washed-out. It took me until the next morning to feel normal again. Then my clinic started using CitraPure® and after my very first dialysis treatment, I immediately felt better. I had my energy back. Now, I feel so good that my wife and I occasionally go out to dinner right after my treatment. CitraPure® has made a very positive impact in my life.”
Tom Barratta, Hemodialysis Patient, USA
- CitraPure
- Study
- MSDS
- Products
Clinical Advantage of
Acetate Free Dialysate Containing Citrate
(Download The study here)
Department of Internal Medicine, Division of Kidney and Dialysis
Hyogo College of Medicine, Nishinomiya, Japan
Takahiro Kuragano and Takeshi Nakanishi
Summary of Results:
• Metabolic acidosis: In the patients with low HCO3
- levels(<20mEq/L) , HCO3
was significantly increased in the AFCD period compared with first AD period.
• Anemia: In the patients with target Hb (≥10g/dL), the dose of ESA decreased in
the AFCD period, while Hb levels were maintained during each dialysate
period. In the patients with lower Hb (<10g/dL) levels, Hb levels increased
significantly in the AFCD period without increasing ESA and iron dose.
• Nutritional condition: In the patients with lower albumin levels, serum albumin
significantly increased in the AFCD period compared with the AD period.
• PTH level: In the patients with normal intact-PTH levels (≥60pg/mL), intact-
PTH and BAP levels did not differ among the 3 periods. In the patients with
hypo-parathyroidism (intact-PTH <60pg/mL), intact-PTH and BAP levels were
significantly increased in the AFCD period.
• These improvements of metabolic acidosis, anemia, malnutrition, and low
turnover bone disease in AFCD period were totally dissipated in the second AD
period.
Conclusion:
1. HD treatment with AFCD may improve the condition of
patients with metabolic acidosis, hyporesponsiveness to
ESA, malnutritional condition, or low turnover bone
disease.
2. The most interesting finding in this study was that AFCD
did not overcorrect HCO3
- and intact-PTH.
CitraPure - Material Safety Data Sheets (MSDS): Download here
CitraPure® Formulations:
Please contact Dial Medical Customer Service for pricing and other available formulations, 800-346-2080, info@dialmedsupply.com.
| CitraPure® is packaged - 4 each 3.78 Liter (1 Gallon) containers per case (42 lbs.) | |||||||||
| Formula | Dilution | Na | Ca | K | Mg | Chloride | Dex | Acetate | Citrate |
| L4-116-4 | 45X | 100.0 | 2.5 | 2.0 | 1.0 | 105.5 | 100 | 0.0 | 2.4 |
| L4-117-4 | 45X | 100.0 | 2.5 | 3.0 | 1.0 | 106.5 | 100 | 0.0 | 2.4 |
| L4-126-4 | 45X | 100.0 | 3.0 | 3.0 | 1.0 | 107.0 | 100 | 0.0 | 2.4 |
| L4-216-4 | 45X | 100.0 | 2.5 | 2.0 | 1.0 | 105.5 | 200 | 0.0 | 2.4 |